New biomanufacturing platform could enable healthcare workers to make vaccines when and where they need them.
Credit: Justin Muir
Membranes unlock potential to vastly increase cell-free vaccine production
By cracking open a cellular membrane, Northwestern University synthetic biologists have discovered a new way to increase production yields of protein-based vaccines by five-fold, significantly broadening access to potentially lifesaving medicines.
In February, the researchers introduced a new biomanufacturing platform that can quickly make shelf-stable vaccines at the point of care, ensuring they will not go to waste due to errors in transportation or storage. In its new study, the team discovered that enriching cell-free extracts with cellular membranes — the components needed to made conjugate vaccines — vastly increased yields of its freeze-dried platform.
The work sets the stage to rapidly make medicines that address rising antibiotic-resistant bacteria as well as new viruses at 40,000 doses per liter per day, costing about $1 per dose. At that rate, the team could use a 1,000-liter reactor (about the size of a large garden waste bag) to generate 40 million doses per day, reaching 1 billion doses in less than a month.
“Certainly, in the time of COVID-19, we have all realized how important it is to be able to make medicines when and where we need them,” said Northwestern’s Michael Jewett, who led the study. “This work will transform how vaccines are made, including for bio-readiness and pandemic response.”
The research was published today (April 22) in the journal Nature Communications.
Jewett is a professor of chemical and biological engineering at Northwestern’s McCormick School of Engineering and director of Northwestern’s Center for Synthetic Biology. Jasmine Hershewe and Katherine Warfel, both graduate students in Jewett’s laboratory, are co-first authors of the paper.
The new manufacturing platform — called in vitro conjugate vaccine expression (iVAX) — is made possible by cell-free synthetic biology, a process in which researchers remove a cell’s outer wall (or membrane) and repurpose its internal machinery. The researchers then put this repurposed machinery into a test tube and freeze-dry it. Adding water sets off a chemical reaction that activates the cell-free system, turning it into a catalyst for making usable medicine when and where it’s needed. Remaining shelf-stable for six months or longer, the platform eliminates the need for complicated supply chains and extreme refrigeration, making it a powerful tool for remote or low-resource settings.
In a previous study, Jewett’s team used the iVAX platform to produce conjugate vaccines to protect against bacterial infections. At the time, they repurposed molecular machinery from Escherichia coli to make one dose of vaccine in an hour, costing about $5 per dose.
“It was still too expensive, and the yields were not high enough,” Jewett said. “We set a goal to reach $1 per dose and reached that goal here. By increasing yields and lowering costs, we thought we might be able to facilitate greater access to lifesaving medicines.”
Jewett and his team discovered that the key to reaching that goal lay within the cell’s membrane, which is typically discarded in cell-free synthetic biology. When broken apart, membranes naturally reassemble into vesicles, spherical structures that carry important molecular information. The researchers characterized these vesicles and found that increasing vesicle concentration could be useful in making components for protein therapeutics such as conjugate vaccines, which work by attaching a sugar unit — that is unique to a pathogen — to a carrier protein. By learning to recognize that protein as a foreign substance, the body knows how to mount an immune response to attack it when encountered again.
1 billion: Number of doses new platform could generate in less than a month
Attaching this sugar to the carrier protein, however, is a difficult, complex process. The researchers found that the cell’s membrane contained machinery that enabled the sugar to more easily attach to the proteins. By enriching vaccine extracts with this membrane-bound machinery, the researchers significantly increased yields of usable vaccine doses.
“For a variety of organisms, close to 30% of the genome is used to encode membrane proteins,” said study co-author Neha Kamat, who is an assistant professor of biomedical engineering at McCormick and an expert on cell membranes. “Membrane proteins are a really important part of life. By learning how to use membrane proteins effectively, we can really advance cell-free systems.”
Original Article: Membranes unlock potential to vastly increase cell-free vaccine production
More from: Northwestern University | Robert R. McCormick School of Engineering and Applied Science
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cell-free vaccine production
- Frederick County Health Department to start offering Novavax vaccine
The Frederick County Health Department on Wednesday will start offering the two-dose, protein-based Novavax COVID-19 vaccine to adults not yet vaccinated against the virus.
- Cell Culture Media Market Worth $14.64 Billion by 2029 - Exclusive Report by Meticulous Research®
Application (Monoclonal Antibody, Diagnostics, Cancer and Stem Cell Research), End User (Pharma & Biotech, Academic)- Global Forecast to 2029Redding, California, Aug. 01, 2022 (GLOBE NEWSWIRE) -- ...
- Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine Abingdon, Oxon, UK, 28 July 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage ...
- Incorporating a coronavirus antigen into MMR vaccine to produce COVID-19 immunity in kids
New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger ...
- How To Accelerate Vaccine Production – And Avoid Speed Bumps
Some of these were unique to this pandemic situation, but racing from a lab – or pilot-scale start – to a finish line of full-scale production ... from this platform for vaccines, with a focus instead ...
Go deeper with Google Headlines on:
Cell-free vaccine production
Go deeper with Bing News on:
Biomanufacturing platform
- Novel Platform Could Help Diagnose Diseases by Isolating Biomarkers in Tears
Dubbed iTEARS, the platform could enable more efficient and less invasive molecular diagnoses for many diseases and conditions, without relying solely on symptoms. Diagnosing diseases often hinges on ...
- MATTERWORKS ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS
Matterworks, Inc., developers of the world’s most powerful metabolomics platform, which accelerates the discovery, development, and manufacturing of biologics and gene therapies, today announces ...
- MATTERWORKS ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS
CAMBRIDGE, Mass, July 19, 2022 /PRNewswire/ -- Matterworks, Inc., developers of the world's most powerful metabolomics platform ... and her network in biomanufacturing across the pharmaceutical ...
- Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
DNase-based oncology platform has the potential to improve outcomes of existing ... "We look forward to leveraging Catalent's proven biomanufacturing expertise at our site in Madison, Wisconsin to ...
- Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
DNase-based oncology platform has the potential to improve ... "We look forward to leveraging Catalent's proven biomanufacturing expertise at our site in Madison, Wisconsin to support the ...